Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc AGRX

Alternate Symbol(s):  AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a... see more

Recent & Breaking News (OTCPK:AGRX)

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 28, 2024

Agile Therapeutics Announces Delisting from Nasdaq

GlobeNewswire March 25, 2024

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

GlobeNewswire March 21, 2024

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

GlobeNewswire March 20, 2024

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

GlobeNewswire March 13, 2024

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

GlobeNewswire February 22, 2024

Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update

GlobeNewswire February 15, 2024

The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost

GlobeNewswire January 23, 2024

Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage Requirement

GlobeNewswire December 12, 2023

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

Accesswire November 22, 2023

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023

GlobeNewswire October 26, 2023

Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2023

Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group

Accesswire September 28, 2023

Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter

Accesswire August 17, 2023

Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2023

Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023

GlobeNewswire July 26, 2023

This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys

Accesswire July 19, 2023

Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women

Accesswire July 18, 2023